Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	TEG platelet mapping system (Haemoscope Corp., Braintree, MA, USA). (Methods, paragraph 4) QIAGEN blood kit (Qiagen, Chatsworth, CA, USA). (Methods, paragraph 5) BaiO BE-2.0 biochip diagnostic analyzer (BaiO Technology Co., Ltd., Shanghai, China). (Methods, paragraph 5)	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	No cell studies were involved	n/a
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	No cell studies were involved	n/a

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	No animal studies were involved	n/a
Animal observed in or captured from the field: Provide species, sex and age where possible	No animal studies were involved	n/a
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID	No animal studies were involved	n/a

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	No plant studies were involved	n/a
Microbes: provide species and strain, unique accession number if available, and source	No plant studies were involved	n/a

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	The Northern Theater General Hospital (Methods, paragraph 1)	
Provide statement confirming informed consent obtained from study participants.	Patients and their families understood the research and signed an informed consent form (Methods, paragraph 1)	
Report on age and sex for all study participants.	Among them are 163 males and 132 females, aged 45-71 years old. (Methods, paragraph 1)	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	DOI: 10.1161/STROKEAHA.119.028713 (Methods, paragraph 4) DOI: 10.1161/STROKEAHA.119.028713 (Methods, paragraph 4)	

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	There is no step-by-step agreement	n/a

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination	The sample size of patients was 249. (Methods, paragraph 1)	
Randomisation		n/a
Blinding	Adopt single blind method.	
Inclusion/exclusion criteria	Inclusion criteria: (1) patients older than 18 years. (2) Patients who took aspirin and clopidogrel. (3) Patients with complete clinical data. (4) The informed consent was signed by patient. Exclusion criteria: (1) patients with epicardial embolism. (2) Patients with a history of clopidogrel allergy. (3) Patients with aspirin allergy history. (4) Patients who took other anticoagulant drugs in March. (5) Patients with hematological diseases. (6) Patients who received intravenous thrombolysis. (Methods, paragraph 2-3)	

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Three times.	
Define whether data describe technical or biological replicates	Technical replicates. (Methods, paragraph 8)	

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Research Ethics Committee of The Northern Theater General Hospital (No.: Y (2021)080). Patients and their families understood the research and signed an informed consent form. (Methods, paragraph 1)	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	No animal experiments were involved	n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Field sample experiment is not involved	n/a

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	Not involved in dual use research	n/a

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Extreme data are excluded and the exclusion criteria are determined in advance.	

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Kaplan-Meier method was used to synthesize cumulative survival curves of patients based on clopidogrel platelet reactivity, CYP2C19 genotype, and CYP2C19 genotype combined with clopidogrel platelet reactivity. Log-rank test was used to evaluate the statistical difference in survival curves, and LSD correction was used for comparison between groups. Multivariate Cox regression analysis was used to determine the related variables affecting clinical endpoint events. (Methods, paragraph 8)	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	Not involved in the new creation of the dataset	n/a
If data are publicly available, provide accession number in repository or DOI or URL.	Data are non-public	n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Public data not used	n/a

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	Relevant data statistics and drawing software can be used normally. (Methods, paragraph 8)	
If code is publicly available, provide accession number in repository, or DOI or URL.	Code is non-public	n/a

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: https://dx.doi.org/10.21037/apm-21-3775